Emerging trends in Sjögren's syndrome: Basic and translational research

Clinical and Experimental Rheumatology

Volumn 30, Issue 5, 2012, Pages 779-784

  Gallo, A ^a   Baldini, C ^b   Teos, L ^a   Mosca, M ^b   Bombardieri, S ^b   Alevizos, I ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Micrornas; Proteomics; Sj gren's syndrome

Indexed keywords

ADENOVIRUS VECTOR; ALPHA DEFENSIN; ALPHA ENOLASE; AMYLASE; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CALGRANULIN B; CATHEPSIN D; CYSTATIN; FATTY ACID BINDING PROTEIN; GUANYLATE BINDING PROTEIN 2; IMMUNOGLOBULIN KAPPA CHAIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MICRORNA; MICRORNA 146A; MYELOID CELL NUCLEAR DIFFERENTIATION ANTIGEN; PARVOVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; GENE TRANSFER; GENOMICS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEOMICS; SALIVARY GLAND; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; TRANSLATIONAL RESEARCH; VIRAL GENE THERAPY; XEROSTOMIA;

ANIMALS; BIOLOGICAL MARKERS; GENE EXPRESSION REGULATION; GENETIC MARKERS; GENETIC THERAPY; GENOMICS; HUMANS; MICRORNAS; PROTEINS; PROTEOMICS; SALIVARY GLANDS; SJOGREN'S SYNDROME; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84870272012     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. TZIOUFAS AG, VOULGARELIS M: Update on Sjögren's syndrome autoimmune epithelitis: from classification to increased neoplasias. Best Pract Res Clin Rheumatol 2007:21:989-1010.
2. MARIETTE X, GOTTENBERG JE: Pathogenesis of Sjögren's syndrome and therapeutic consequences. Curr Opin Rheumatol 2010;22:471-7.
3. RAMOS-CASALS M, BRITO-ZERÓN P, SISÓALMIRALL A, BOSCH X: Primary Sjögren's syndrome. BMJ 2012;344:e3821.
4. SHIBOSKI SC, SHIBOSKI CH, CRISWELL L et al:. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012;64:475-87.
5. RAMOS-CASALS M, TZIOUFAS AG, STONE JH, SISÓ A, BOSCH X: Treatment of primary Sjögren's syndrome: a systematic review. JAMA 2010;304:452-60.
6. BALDINI C, TALARICO R, TZIOUFAS AG, BOMBARDIERI S: Classification criteria for Sjögren's syndrome: A critical review. J Autoimmun 2012;39:9-14.
7. KAPSOGEORGOU EK, GOURZI VC, MANOUSSAKIS MN, MOUTSOPOULOS HM, TZIOUFAS AG: Cellular microRNAs (miRNAs) and Sjögren's syndrome: candidate regulators of autoimmune response and autoantigen expression. J Autoimmun 2011;37:129-35.
8. FERRACCIOLIG, DE SANTIS M, PELUSO G et al.: Proteomic approaches to Sjögren's syndrome: a clue to interpret the pathophysiology and organ involvement of the disease. Autoimmun Rev 2010;9:622-6.
9. ALEVIZOS I, ILLEI GG: MicroRNAs in Sjögren's syndrome as a prototypic autoimmune disease. Autoimmun Rev 2010;9:618-21.
10. BALDINI C, GIUSTI L, BAZZICHI L, LUCACCHINI A, BOMBARDIERI S: Proteomic analysis of the saliva: a clue for understanding primary from secondary Sjögren's syndrome? Auloimmun Rev 2008;7:185-91.
11. GIUSTI L, BALDINI C, BAZZICHI L, BOMBARDIERI S, LUCACCHINI A: Proteomic diagnosis of Sjögren's syndrome. Expert Rev Proteomics 2007;4:757-67.
12. GIUSTI L, BALDINI C, BAZZICHI L et al.: Proteome analysis of whole saliva: a new tool for rheumatic diseases-the example of Sjögren's syndrome. Proteomics 2007;7:1634-43.
13. ROESCHER N, TAK PP, ILLEI GG: Cytokines in Sjögren's syndrome: potential therapeutic targets. Ann Rheum Dis 2010;69:945-8.
14. DELALEU N, JONSSON MV, APPEL S, JONSSON R: New concepts in the pathogenesis of Sjögren's syndrome. Rheum Dis Clin North Am 2008;34:833-45, vii.
15. ALEVIZOS I, ALEXANDER S, TURNER RJ, ILLEI GG: MicroRNA expression profiles as biomarkers of minor salivary gland inflammation and dysfunction in Sjögren's syndrome. Arthritis Rheum 2011;63:535-44.
16. GALLO A, TANDON M, ALEVIZOS I, ILLEI GG: The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 2012;7:e30679.
17. BALDINI C, GIUSTI L, CIREGIA F: Proteomic analysis of saliva: a unique tool to distinguish primary Sjögren's syndrome from secondary Sjögren's syndrome and other sicca syndromes. Arthritis Res Ther 2011;13:R194.
18. KANG EH, LEE YJ, HYON JY, YUN PY, SONG YW: Salivary cytokine profiles in primary Sjögren's syndrome differ from those in non-Sjögren sicca in terms of TNF-alpha levels and Th-l/Th-2 ratios. Clin Exp Rheumatol 2011;29:970-6.
19. HE J, QIANG L, DING Y, WEI P, LI YN, HUA H, LI ZG: The role of muscarinic acetylcholine receptor type 3 polypeptide (M3RP205-220) antibody in the saliva of patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2012;30:322-6.
20. TANDON M, GALLO A, JANG SI, ILLEI GG, ALEVIZOS: Deep sequencing of short RNAs reveals novel microRNAs in minor salivary glands of patients with Sjögren's syndrome. Oral Dis 2012;18:127-31.
21. GREGORY RI, YAN KP, AMUTHAN G et al:. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004;432:235-40.
22. LEE Y, KIM M, HAN J et al.: MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004;23:4051-60.
23. YI R, QIN Y, MACARA IG, CULLEN BR: Exportin-5 mediates the nuclear export of premicroRNAs and short hairpin RNAs. Genes Dev 2003;17:3011-6.
24. CHUA JH, ARMUGAM A, JEYASEELAN K: MicroRNAs: biogenesis, function and applications. Curr Opin Mol Ther 2009;11:189-99.
25. ROBB GB, RANA TM: RNA helicase A interacts with RISC in human cells and functions in RISC loading. Mol Cell 2007;26:523-37.
26. KONG YW, CANNELL IG, DE MOOR CH et al:. The mechanism of micro-RNA-mediated translation repression is determined by the promoter of the target gene. Proc Natl Acad Sci USA 2008;105:8866-71.
27. MIRANDA K, HUYNH T, TAY YC et al:. A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006;126:1203-17.
28. PAULEY KM, STEWART CM, GAUNA AE et al.: Altered miR-146a expression in Sjögren's syndrome and its functional role in innate immunity. Eur J Immunol 2011;41:2029-39.
29. VAN ROOIJ E, PURCELL AL, LEVIN AA: Developing MicroRNA therapeutics. Circ Res 2012;110:496-507.
30. PATTERSON SD: Proteomics: evolution of the technology. Biotechniques 2003;35:440-4.
31. HU S, LOO JA, WONG DT: Human saliva proteome analysis and disease biomarker discovery. Expert Rev Proteomics 2007;4:531-8.
32. GIUSTI L, BAZZICHI L, BALDINI C et al:. Specific proteins identified in whole saliva from patients with diffuse systemic sclerosis. J Rheumatol 2007;34:2063-9.
33. GIACOMELLI C, BAZZICHI L, GIUSTI L et al:. MALDI-TOF and SELDI-TOF analysis: "tandem" techniques to identify potential bio-marker in fibromyalgia. Reumatismo 2011;63:165-70.
34. GIUSTI L, BALDINI C, CIREGIA F et al:. Is GRP78/BiP a potential salivary biomarker in patients with rheumatoid arthritis? Proteomics Clin Appl 2010;4:315-24.
35. AL-TARAWNEH SK, BORDER MB, DIBBLE CF, BENCHARIT S: Defining salivary biomarkers using mass spectrometry-based proteomics: a systematic review. OMICS 2011;15:353-61.
36. WONG DT: Salivary diagnostics: scientific and clinical frontiers. Adv Dent Res 2011;23:350-2.
37. TOMOSUGI N, KITAGAWA K, TAKAHASHI N, SUGAI S, ISHIKAWA I: Diagnostic potential of tear proteomic patterns in Sjögren's syndrome. J Proteome Res 2005;4:820-5.
38. BALDINI C, GALLO A, PEREZ P, MOSCA M, ALEVIZOS I, BOMBARDIERI S: Saliva as an ideal milieu for emerging diagnostic approaches in primary Sjögren's syndrome. Clin Exp Rheumatol 2012 Sep. 25 [Epub ahead of print].
39. PELUSO G, DE SANTIS M, INZITARI R et al:. Proteomic study of salivary peptides and proteins in patients with Sjögren's syndrome before and after pilocarpine treatment. Arthritis Rheum 2007;56:2216-22.
40. ITO K, FUNAYAMA S, HITOMI Y et al:. Proteome analysis of gelatin-bound salivary proteins in patients with primary Sjögren's syndrome: identification of matrix metalloproteinase-9. Clin Chim Acta 2009;403:269-71.
41. HU S, XIE Y, RAMACHANDRAN P et al:. Large-scale identification of proteins in human salivary proteome by liquid chromatography/mass spectrometry and two-dimensional gel electrophoresis-mass spectrometry. Proteomics 2005;5:1714-28.
42. HU S, GAO K, POLLARD R et al:. Preclinical validation of salivary biomarkers for primary Sjögren's syndrome. Arthritis Care Res (Hoboken) 2010;62:1633-8.
43. FLEISSIG Y, DEUTSCH O, REICHENBERG E et al:. Different proteomic protein patterns in saliva of Sjögren's syndrome patients. Oral Dis 2009;15:61-8.
44. BALDINI C, GIUSTI L, CIREGIA F et al:. Correspondence between salivary proteomic pattern and clinical course in primary Sjögren's syndrome and non-Hodgkin's lymphoma: a case report. J Transl Med 2011;9:188.
45. RYU OH, ATKINSON JC, HOEHN GT, ILLEI GG, HART TC: Identification of parotid salivary biomarkers in Sjögren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis. Rheumatology (Oxford) 2006;45:1077-86.
46. HJELMERVIK TO, JONSSON R, BOLSTAD AI: The minor salivary gland proteome in Sjögren's syndrome. Oral Dis 2009;15:342-53.
47. HU S, WANG J, MEIJER J et al:. Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis Rheum 2007;56:3588-600.
48. NAVAZESH M: Methods for collecting saliva. Ann N Y Acad Sci 1993;694:72-7.
49. HYPHANTIS T, MANTIS D, VOULGARI PV, TSIFETAKI N, DROSOS AA: The psychological defensive profile of primary Sjögren's syndrome patients and its relationship to health-related quality of life. Clin Exp Rheumatol 2011;29:485-93.
50. VOULGARELIS M, TZIOUFAS AG, MOUTSOPOULOS HM: Mortality in Sjögren's syndrome. Clin Exp Rheumatol 2008;26(Suppl. 51):S66-71.
51. VAN OERS ML, BOSSEMA ER, THOOLEN BJ et al:. Variability of fatigue during the day in patients with primary Sjögren's syndrome, systemic lupus erythematosus, and rheumatoid arthritis. Clin Exp Rheumatol 2010;28:715-21.
52. BALDINI C, PEPE P, LUCIANO N et al:. A clinical prediction rule for lymphoma development in primary Sjögren's syndrome. J Rheumatol 2012;39:804-8.
53. HU S, ZHOU M, JIANG J et al:. Systems biology analysis of Sjögren's syndrome and mucosa-associated lymphoid tissue lymphoma in parotid glands. Arthritis Rheum 2009;60:81-92.
54. KOK MR, YAMANO S, LODDE BM et al:. Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren's syndrome. Hum Gene Ther 2003;14:1605-18.
55. HALSE A, TENGNER P, WAHREN-HERLENIUS M, HAGA H, JONSSON R: Increased frequency of cells secreting interleukin-6 and interleukin-10 in peripheral blood of patients with primary Sjögren's syndrome. Scand J Immunol 1999;49:533-8.
56. ROESCHER N, VOSTERS JL, YIN H, ILLEI GG, TAK PP, CHIORINI JA: Effect of soluble ICAM-1 on a Sjögren's syndrome-like phenotype in NOD mice is disease stage dependent. PLoS One 2011;6:el9962.
57. VOSTERS JL, ROESCHER N, ILLEI GG, CHIORINI JA, TAK PP: TACI-Fc gene therapy improves autoimmune sialadenitis but not salivary gland function in non-obese diabetic mice. OralDis 2012;18:365-74.
58. NGUYEN CQ et al:. Pathogenic effect of interleukin-17A in induction of Sjögren's syndrome-like disease using adenovirus-mediated gene transfer. Arthritis Res Ther 2010;12:R220.
59. VOSTERS JL et al:. Local expression of tumor necrosis factor-receptor 1 immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome. Arthritis Res Ther 2009;11:R189.
60. BAUM BJ, ZHENG C, ALEVIZOS I et al.: Development of a gene transfer-based treatment for radiation-induced salivary hypofunction. Oral Oncol 46:4-8.
61. CHEN Y, DU D, WU J et al:. Inhibition of hepatitis B virus replication by stably expressed shRNA. Biochem Biophys Res Commun 2003;311:398-404.
62. HADJ-SLIMANE R, LEPELLETIER Y, LOPEZ N, GARBAY C, RAYNAUD: Short interfering RNA (siRNA), a novel therapeutic tool acting on angiogenesis. Biochimie 2007;89:1234-44.